Source:http://linkedlifedata.com/resource/pubmed/id/17618721
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6
|
| pubmed:dateCreated |
2007-7-27
|
| pubmed:abstractText |
Modulations of serotonergic and noradrenergic systems are thought to be critical to the therapeutic effect of most antidepressants, and their efficacies have been shown to depend on a functional polymorphism within the promoter region of the serotonin transporter gene (5-HTTLPR). Mirtazapine has a dual-action profile, combining the enhancement of the noradrenergic neurotransmitter system with specific actions on particular serotonergic receptor subtypes. The goal of this study was to elucidate whether the 5-HTTLPR polymorphism is associated with the mirtazapine antidepressant response in subjects with major depressive disorder (MDD). One hundred and one MDD patients were evaluated during 4 weeks of mirtazapine treatment. The severity of depression was assessed with the 21-item Hamilton Depression Rating scale, and the 5-HTTLPR genotypes in the patients were determined using the polymerase chain reaction. Our results showed that responses at the 2nd and 4th weeks were significantly better for the s/s genotype of the 5-HTTLPR polymorphism than for l-allele carriers. These results support our hypothesis that the response to noradrenergic and specific serotonergic antidepressants is significantly associated with the 5-HTTLPR polymorphism.
|
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Aug
|
| pubmed:issn |
0278-5846
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
15
|
| pubmed:volume |
31
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1317-21
|
| pubmed:dateRevised |
2008-11-21
|
| pubmed:meshHeading |
pubmed-meshheading:17618721-Adult,
pubmed-meshheading:17618721-Analysis of Variance,
pubmed-meshheading:17618721-Antidepressive Agents, Tricyclic,
pubmed-meshheading:17618721-Chi-Square Distribution,
pubmed-meshheading:17618721-DNA Mutational Analysis,
pubmed-meshheading:17618721-Depressive Disorder, Major,
pubmed-meshheading:17618721-Female,
pubmed-meshheading:17618721-Gene Frequency,
pubmed-meshheading:17618721-Genotype,
pubmed-meshheading:17618721-Humans,
pubmed-meshheading:17618721-Male,
pubmed-meshheading:17618721-Mianserin,
pubmed-meshheading:17618721-Middle Aged,
pubmed-meshheading:17618721-Pharmacogenetics,
pubmed-meshheading:17618721-Polymorphism, Genetic,
pubmed-meshheading:17618721-Promoter Regions, Genetic,
pubmed-meshheading:17618721-Psychiatric Status Rating Scales,
pubmed-meshheading:17618721-Serotonin Plasma Membrane Transport Proteins
|
| pubmed:year |
2007
|
| pubmed:articleTitle |
Association study of the serotonin transporter promoter polymorphism and mirtazapine antidepressant response in major depressive disorder.
|
| pubmed:affiliation |
Depression Center, Korea University, Seoul, Republic of Korea.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|